FILING ANALYSIS · MONDAY, NOVEMBER 16

Jasper Therapeutics, Inc. JSPR — 8-K: Results of Operations and Financial Condition

neutral

The company reported progress in its development programs, including the completion of enrollment in the first cohort of its Phase 2 renal basket study, and announced a private placement resulting in gross proceeds of approximately $132.0 million, but also underwent a 1-for-30 reverse stock split, which may indicate dilution and financial pressure

The filing

8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+